The strings “Cagri 1S”, “Cagri 2T”, and “Cagri 3R” likely refer to experimental, research-grade, or compounded peptide blends (often combining Cagrilintide with other analogs) rather than standardized pharmaceuticals. The FDA-approved or Phase-3 trial medication CagriSema (combining cagrilintide and semaglutide) uses standard weekly doses measured in milligrams (e.g., 2.4 mg).
Key Differences in Research Peptides
- Cagri 1S: Typically a blend of Cagrilintide and Semaglutide (the active ingredient in Wegovy).
- Cagri 2T: Typically a blend of Cagrilintide and Tirzepatide (the active ingredient in Mounjaro/Zepbound).
- Cagri 3R: Typically a triple-agonist blend of Cagrilintide, Tirzepatide, and a third compound (such as Retatrutide)




Reviews
There are no reviews yet.